Skip to main
CGON

CGON Stock Forecast & Price Target

CGON Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 55%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

CG Oncology Inc. is poised for significant growth with projected launch sales of its candidate, cretostimogene grenadenorepvec (Creto), reaching approximately $2.6 billion by 2034, supported by premium pricing strategies that enhance the long-term market outlook. The company's differentiation through Creto's efficacy and durability, evidenced by favorable data from the BOND-003 study, positions it advantageously for regulatory approval and commercial adoption, bolstering confidence in its potential market share. Additionally, the opportunity to expand into BCG-naïve and BCG-exposed populations enhances the upside potential, while management's readiness for manufacturing and commercialization addresses key investor concerns, underpinning a positive trajectory for CG Oncology's stock.

Bears say

The financial outlook for CG Oncology appears negative due to several key concerns regarding its pipeline and competitive positioning. There are significant risks associated with potential negative trial readouts, slower-than-anticipated enrollment in clinical trials, and adverse regulatory decisions, all of which could impede the company’s prospects for commercialization. Furthermore, the possibility of challenges to its intellectual property and the emergence of competitive therapies that offer superior results further complicate CG Oncology's market potential, raising doubts among investors about the sustainability of its stock performance.

CGON has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 55% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CG oncology Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CG oncology Inc (CGON) Forecast

Analysts have given CGON a Buy based on their latest research and market trends.

According to 11 analysts, CGON has a Buy consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $62.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $62.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CG oncology Inc (CGON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.